Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | F2R | P25116 | 13/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | DDX3X | O00571 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22362619 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2F2RNPC1RAB9A | |
| SCHEMBL8402949 | 0.89 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2PTGS1KMT2ADDX3X | |
| SCHEMBL11575251 | 0.85 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2F2RNPC1RAB9A | |
| SCHEMBL9810110 | 0.84 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2NPC1RAB9APTGS1 | |
| SCHEMBL882776 | 0.82 | NPC1 (0.75) | ALDH1A1SMN1; SMN2F2RNPC1RAB9A | |
| SCHEMBL3663484 | 0.82 | KMT2A (0.61) | ALDH1A1F2RNPC1RAB9AKMT2A | |
| SCHEMBL882734 | 0.81 | KMT2A (0.80) | ALDH1A1SMN1; SMN2F2RNPC1RAB9A | |
| SCHEMBL28493350 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2PTGS1KMT2ADDX3X | |
| SCHEMBL811056 | 0.81 | KCNK3 (0.68) | ALDH1A1SMN1; SMN2F2RPTGS1KMT2A | |
| SCHEMBL27645970 | 0.81 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2F2RNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130743-B2 | Heterocyclic ligands of PAR1 and methods of use | MARQUETTE UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200270224-A1 | Heterocyclic Ligands of PAR1 and Methods of Use | MARQUETTE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20130331411-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2013-12-12 | — | — | US | disclosed |
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7291632-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291632-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060287363-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht 1f agonists | ELLI LILLY AND COMPANY (US) | 2006-12-21 | — | — | US | disclosed |
| CN-1849307-A | As 5-HT1FSubstituted 2-carbonylamino-6-agonistsPiperidinylaminopyridines and substituted 1-carbonylamino-3-piperidinylaminophenyls | LILLY CO ELI (US) | 2006-10-18 | — | — | CN | disclosed |
| EP-1663971-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | Eli Lilly and Company (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005035499-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 2723/4885SMN1; SMN2 3135/4885F2R 3269/4885 |
| US-20130331411-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | ALDH1A1 1289/4885SMN1; SMN2 1938/4885F2R 1/4885 |
| US-20060287363-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht 1f agonists | HTR1F, HTR1A, HTR3B | ALDH1A1 1980/4885SMN1; SMN2 1901/4885F2R 58/4885 |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 2723/4885SMN1; SMN2 3135/4885F2R 3269/4885 |
| US-20200270224-A1 | Heterocyclic Ligands of PAR1 and Methods of Use | F2R, F2RL1, PLAT | ALDH1A1 3966/4885SMN1; SMN2 1833/4885F2R 1/4885 |
| US-11130743-B2 | Heterocyclic ligands of PAR1 and methods of use | F2R, F2RL1, PLAT | ALDH1A1 3966/4885SMN1; SMN2 1833/4885F2R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.